Subscriber ContentRead Preview
Hand it to the graphic chip maker for signing deals with Samsung and Atmel to develop large touchscreen tablets.
Subscriber ContentRead Preview
BABs' fate uncertain, but taxes are more likely to be higher than lower.
Subscriber Content Read Preview
Achillion Pharmaceuticals could be a takeout candidate in 2011.
Subscriber Content Read Preview
MGM, Nokia and Emergency Medical fell. Hercules Offshore rose.
Subscriber Content Read Preview
The telecom-equipment firm is seeing intensifying competition.
Subscriber Content Read Preview
Delek, Frontier Oil, Holly and Western Refining are well positioned.
Subscriber Content Read Preview
The biopharmaceutical firm is facing revenue and gross-margin pressure.
Subscriber Content Read Preview
With the stock riding high, seven insiders, including the CEO, recently sold about $18 million in shares.
Subscriber Content Read Preview
Buy stock and sell puts on CBOE to build a position in a company destined to be acquired.
Subscriber Content Read Preview
After idling for two months, the sector is poised to power ahead.
Subscriber Content Read Preview
Subscriber Content Read Preview
Subscriber Content Read Preview
Subscriber Content Read Preview
The tech titan tops our global ranking for the second straight year, followed by Amazon and Berkshire Hathaway.
Editor and President Ed Finn explains how you can use Barron's to become a better investor. Watch video
SIRI | SCHW | APOL | CBOE | EMC |
AMTD | C | CAM | CVX | GOOG |
DAG | NLR | FDX | ARMH | AKAM |
BP | AMD | AAPL | EMS | ABX |
Subscriber Content Read Preview
Slowing growth abroad will likely be a drag for the U.S.
The chief investment officer of Rosenau/Paul thinks the time is finally here for large-cap stocks with growing dividends. Here's what she's been buying.
Regardless of what path Egypt now follows, a leading analyst says the price of oil is headed toward $300 a barrel based on basic supply-and-demand forces.
With drug stocks ailing, companies like Abbott and Medtronic should start shedding non-core businesses. For investors, it would be just the right medicine.
Business ethicists and advocates for corporate social responsibility are playing a dangerous game.
This feature tracks the performance of stocks Barron's has written about during 2011 -- both favorably and critically. For stocks featured in Barron's print magazine, prices are measured from the Friday before publication date to their current price. For stocks featured on Barrons.com, prices are measured from the trading day of publication date to their current price. This list includes U.S. stocks only, including ADRs, but not foreign stocks.